Search / Trial NCT00000929

A Study of the Effects of Advantage 24 on the Rectum

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of February 21, 2024

Completed

Keywords

Sexual Partners Homosexuality, Male Anti Infective Agents Patient Compliance Nonoxynol Rectum

Description

Chemical barriers which can be controlled by the receptive partner to prevent transmission of HIV and other sexually transmitted diseases (STDs) are among the highest priorities for research and development. Advantage 24 is a contraceptive gel containing nonoxynol-9 (N-9). This study provides information on the safety of N-9 in a bioadhesive gel formulated for use by MSM during anal intercourse. Safety is assessed for both HIV-positive and HIV-negative men because HIV-positive men may be at increased risk for toxicity due to other HIV-related conditions. Participants are divided into 4 coh...

Gender

Male

Eligibility criteria

  • Exclusion Criteria
  • Co-existing Condition:
  • Participants with the following symptoms or conditions are excluded:
  • Positive HSV-2 serology (HIV-negative participants only).
  • Positive syphilis by Venereal Disease Research Laboratory (VDRL) serology and Fluorescent Treponemal Antibody (FTA) or Microhemagglutination Assay (MHA).
  • Receptive partners with the following additional symptoms or conditions are excluded:
  • Rectal gonorrhea or chlamydia by culture.
  • Active rectal inflammation, ulceration, or fissures.
  • Insertive partners with the following additional symptoms or conditions are excluded:
  • Penile or urethral irritation, rashes, or lesions.
  • Penile or scrotal piercing.
  • Concurrent Medication:
  • Excluded for receptive partners:
  • -
  • Anticoagulant, including warfarin and heparin.
  • Participants with the following prior conditions are excluded:
  • Sensitivity or irritative symptoms when using N-9 or when exposed to latex.
  • Three or more Herpes Simplex 2 Virus (HSV-2) outbreaks within 12 months prior to screening (HIV-positive participants only).
  • One or more HSV-2 outbreaks within 6 months prior to screening (HIV-positive participants only).
  • Receptive partners with the following additional prior conditions are excluded:
  • Diagnosed inflammatory bowel disease, ulcerative colitis, Crohn's disease, or rectal malignancy.
  • Diagnosed bleeding disorder, including hemophilia and thrombocytopenia.
  • Rectal surgery including fistulectomy.
  • Prosthetic heart valve or diagnosis of a valvular abnormality.
  • Hemorrhoidectomy within 6 months prior to screening.
  • Rectal burning, tenesmus, bleeding, or irritation in the week prior to screening.
  • Diarrhea (more than 3 stools per day) in the week prior to screening.
  • Use of rectally-inserted sex toys, practiced receptive fisting, or rectal douching in the week prior to screening.
  • Insertive partners with the following additional prior conditions are excluded:
  • Urethral burning or discharge in the week prior to screening.
  • Prior Medication:
  • Excluded for receptive partners:
  • Use of laxatives in the week prior to screening.
  • Participants meet the following criteria:
  • HIV-negative or HIV-positive; participant's partner must be the same serostatus.
  • Plan to have anal intercourse only with the study partner for the duration of the study. During all episodes in which Advantage 24 is used, one partner is exclusively insertive and the other partner is exclusively receptive.
  • Sexual partner of at least 3 months is eligible and agrees to participate.
  • Agree to use non-N-9 lubricant and condoms for all episodes of anal intercourse.
  • Avoid use of Advantage 24 for purposes other than specified by the protocol.
  • Receptive partners meet the following additional criteria:
  • Plan to have receptive anal intercourse with the study partner with Advantage 24 applied rectally, and using N-9 lubricant and condoms, at the couple's usual frequency (at least 3 times per week).
  • Agree to apply the specified amount of Advantage 24 daily to the rectum.
  • Avoid use of laxatives, use of rectally-inserted sex toys, receptive fisting, and rectal douching.
  • Insertive partners meet the following additional criteria:
  • Plan to have insertive anal intercourse with the study partner with Advantage 24 applied to the glans of the penis, and using non-N-9 lubricant and condoms, at the couple's usual frequency (at least 3 times per week).
  • Agree to apply the specified amount of Advantage 24 daily to the penis.

Attachments

readout_NCT00000929_2024-02-21.pdf

4.5 MB

NCT00000929_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Seattle, Washington, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0